Related Experiment Video

Updated: Jul 15, 2026

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations
09:25

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations

Published on: January 10, 2015

Interactions between 2,3,7,8-TCDD and PCBs as tumor promoters: limitations of TEFs

D Wölfle1

  • 1Department of Toxicology, University of Hamburg Medical School, Germany.

Teratogenesis, Carcinogenesis, and Mutagenesis
|January 1, 1997
PubMed

Insights

Assessing carcinogenic risk from dioxins, furans, and biphenyls is complex. Interactions between these compounds, like polychlorinated biphenyls (PCBs), can alter tumor promotion, challenging current risk assessment methods.

Area of Science:

  • Environmental Chemistry
  • Toxicology
  • Molecular Biology

Background:

  • Polychlorinated dioxins (PCDDs), furans (PCDFs), and biphenyls (PCBs) pose carcinogenic risks, but their assessment is complicated by species- and tissue-specific responses.
  • These compounds accumulate as complex mixtures in the environment and tissues, necessitating a broader risk assessment approach.
  • Existing Toxic Equivalency Factors (TEFs) may not fully capture the interactive effects of these compounds on Ah receptor-mediated responses.

Purpose of the Study:

  • To investigate the tumor-promoting interactions of TCDD and various PCBs using an in vitro malignant transformation assay.
  • To evaluate the role of coplanar (PCB 126) and diortho-substituted (PCB 153) PCBs in tumor promotion.
  • To determine if the TEF approach is sufficient for assessing the carcinogenic potential of complex PCB mixtures.

Main Methods:

  • Established an in vitro assay using carcinogen-initiated C3H/M2 mouse fibroblasts to measure malignant transformation.
  • Treated cells with TCDD, PCB 126 (a potent Ah receptor agonist), and PCB 153 (a diortho-substituted PCB without a TEF value).
  • Analyzed the promoting effects of individual compounds and mixtures of TCDD and PCBs on malignant transformation.

Main Results:

  • Both PCB 126 and PCB 153 demonstrated tumor-promoting activity in the in vitro assay.
  • A mixture of PCB 126 and TCDD exhibited additive tumor-promoting effects.
  • PCB 153 antagonized the tumor-promoting effects of TCDD, indicating complex interactions.

Conclusions:

  • The TEF approach may be insufficient for accurately estimating the tumor-promoting activities of PCDDs, PCDFs, and PCBs.
  • Diortho-substituted PCBs, like PCB 153, can significantly modulate the carcinogenic effects of other dioxin-like compounds.
  • Comprehensive risk assessments must consider the complex interactions and tissue-specific accumulation of various PCBs.

More Related Videos

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)

Published on: May 10, 2016

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA)04:12

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA)

Published on: December 19, 2019

Related Concept Videos

Toxic Reactions: Overview01:26

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Bioactivation and Tissue Toxicity01:25

Bioactivation and Tissue Toxicity

Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...